InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
- Reported positive preclinical data in both its Alzheimer's and dry AMD programs
- Closed Fiscal Q3 with cash position of US$7.9 million
- 其阿爾茨海默氏症和乾性 AMD 項目均報告了積極的臨床前數據
- 第三財季結束，現金狀況爲790萬美元
Vancouver, British Columbia–(Newsfile Corp. – May 14, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, today announced financial results and business update for the third quarter of the fiscal year 2024, which ended March 31, 2024.
不列顛哥倫比亞省溫哥華——（新聞檔案公司，2024年5月14日）——專注於開發專有小分子候選藥物管道的臨床階段製藥公司InMed Pharmicals Inc.（納斯達克股票代碼：INM）（“InMed” 或 “公司”）今天公佈了截至2024年3月31日的2024財年第三季度的財務業績和業務更新。
The Company's full financial statements and related MD&A for the third quarter ended March 31, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
公司截至2024年3月31日的第三季度的完整財務報表和相關管理與分析可在以下網址查閱 www.inmedpharma.com， www.sedar.com 並在 www.sec.gov。
Eric A. Adams, InMed President and CEO, commented, "The third quarter of fiscal year 2024 was another positive quarter for the Company as we continue to make exciting progress in our pharmaceutical pipeline and deliver steady growth in our commercial business. Last month we announced important updates in our two preclinical programs in the treatment of Alzheimer's disease ("ALZ") and dry Age-related Macular Degeneration ("dry AMD"). Both programs utilize proprietary small molecule drug candidates activating both the CB1 / CB2 receptors as well as other disease-relevant receptors. We are highly encouraged by the positive findings and we are committed to further advancing our research in these two highly underserved indications."
InMed總裁兼首席執行官埃裏克·亞當斯評論說：“2024財年第三季度對公司來說又是一個積極的季度，因爲我們的藥品管道繼續取得令人興奮的進展，商業業務實現穩步增長。上個月，我們宣佈了治療阿爾茨海默氏病（“ALZ”）和乾性年齡相關性黃斑變性（“乾性AMD”）的兩個臨床前項目的重要更新。這兩個項目都使用專有的小分子候選藥物來激活CB1/CB2受體以及其他與疾病相關的受體。這些積極的發現令我們深受鼓舞，我們致力於進一步推進對這兩個服務嚴重不足的適應症的研究。”
Adams continued, "Revenues from the BayMedica commercial business remain consistent with the previous quarter and BayMedica operated as a profitable commercial business unit in the current quarter. We remain optimistic for the sector as more brands start to incorporate rare cannabinoids into their product portfolios."
亞當斯繼續說：“BayMedica商業業務的收入與上一季度保持一致，BayMedica在本季度作爲盈利的商業業務部門運營。隨着越來越多的品牌開始將稀有大麻素納入其產品組合，我們對該行業仍然持樂觀態度。”
Business update
業務更新
Pharmaceutical Development Programs
藥物開發計劃
INM-901: A multipronged approach in treatment of Alzheimer's disease.
INM-901：一種治療阿爾茨海默病的多管齊下的方法。
INM-901 is a proprietary small molecule drug candidate being developed as a potential treatment for ALZ employing multiple mechanisms of actions. On April 4, 2024, the Company announced additional preclinical data demonstrating INM-901's positive pharmacological effects. Results included:
INM-901 是一種專有的小分子候選藥物，正在開發作爲採用多種作用機制的 ALZ 的潛在治療方法。2024 年 4 月 4 日，該公司公佈了更多臨床前數據，這些數據表明 INM-901 具有積極的藥理作用。結果包括：
- INM-901 is a preferential signaling agonist of the CB1/CB2 receptors and impacts the PPAR signaling pathway;
- INM-901 demonstrates reduced neuroinflammation and improved neuronal function; and
- mRNA data from INM-901 preclinical studies support the observations made in the previously released behavior studies in locomotor activity, cognition and memory.
- INM-901 是 CB1/CB2 受體的優先信號激動劑，會影響 PPAR 信號通路；
- INM-901 顯示出神經炎症減少和神經元功能改善；以及
- 來自 INM-901 臨床前研究的 mRNA 數據支持先前發佈的運動活動、認知和記憶行爲研究中的觀察。
InMed continues to accelerate the development of its ALZ program, with long-term behavioural and mechanism of action / receptor interaction studies currently underway. Data read-out expected in calendar 3Q 2024.
InMed繼續加快其ALZ計劃的發展，目前正在進行長期行爲和作用機制/受體相互作用研究。預計將在2024年第三季度公佈數據。
Additionally, the Company recently announced the addition of Dr. David G. Morgan, a leader in neurodegenerative disease, to its Scientific Advisory Board ("SAB"), reinforcing the Company's commitment to advancing it's INM-901 program.
此外，該公司最近宣佈將神經退行性疾病領域的負責人戴維·摩根博士加入其科學顧問委員會（“SAB”），這加強了公司推進其 INM-901 計劃的承諾。
INM-089: Neuroprotection in the treatment of dry AMD
INM-089：乾性 AMD 治療中的神經保護
INM-089 is another proprietary small molecule drug candidate being studied in the treatment of Age-related Macular Degeneration ("AMD"). In April, the Company announced additional preclinical data for INM-089 further demonstrating positive pharmacological effects. Results from INM-089 preclinical studies included:
INM-089 是另一種正在研究的專有小分子候選藥物，用於治療與年齡相關的黃斑變性（“AMD”）。4月，該公司公佈了更多的 INM-089 臨床前數據，進一步顯示出積極的藥理作用。INM-089 臨床前研究的結果包括：
- Data indicates that INM-089 may be more effective as a therapeutic treatment for dry AMD compared to neovascular, or wet, AMD;
- More specifically, data suggests INM-089 may be an important candidate for geographic atrophy ("GA") which is common in more advanced cases of dry AMD;
- Enhanced neuroprotection of photoreceptors as well as improved photoreceptor function;
- Improved integrity of retinal pigment epithelium; and
- Reduction in extracellular autofluorescent deposits, a hallmark of dry AMD.
- 數據表明，與新生血管性或溼性 AMD 相比，INM-089 作爲乾性 AMD 的治療可能更有效；
- 更具體地說，數據表明，INM-089 可能是地理萎縮（“GA”）的重要候選者，這在更晚期的乾性 AMD 病例中很常見；
- 增強對光感受器的神經保護並改善感光器功能；
- 改善視網膜色素上皮的完整性；以及
- 減少細胞外自熒光沉積，這是乾性 AMD 的標誌。
The Company has strategically prioritized the utilization of its proprietary small molecule drug candidates in its drug development initiatives, resulting in the INM-089 program for the treatment of dry AMD taking precedence over the INM-088 program in the treatment of glaucoma. Therefore, the Company will not be advancing INM-088 in the immediate future. Notably, the initial research and data from the INM-088 program have played an instrumental role in shaping the development of INM-089 program.
該公司已戰略性地在其藥物開發計劃中優先使用其專有的小分子候選藥物，這使得治療乾性 AMD 的 INM-089 計劃在青光眼治療方面優先於 INM-088 計劃。因此，該公司在不久的將來不會推進 INM-088。值得注意的是，來自 INM-088 計劃的初步研究和數據在塑造 INM-089 計劃的發展方面發揮了重要作用。
BayMedica Commercial Business
BayMedica 商業業務
BayMedica revenues were $3.3 million for the nine months ended March 31, 2024, compared with $1.8 million for the nine months ended March 31, 2023, representing 83% growth over the same period last year. Quarter over quarter revenue has remained flat this period with sales of $1.2 million, same as the previous quarter. BayMedica operated as a profitable business unit this quarter and continues to make progress lowering manufacturing costs that should incrementally improve margins over time. While we are optimistic about the long-term growth potential in the rare cannabinoids sector, we expect revenue to fluctuate in future quarters.
截至2024年3月31日的九個月中，BayMedica的收入爲330萬美元，而截至2023年3月31日的九個月爲180萬美元，比去年同期增長了83％。同期同比收入保持平穩，銷售額爲120萬美元，與上一季度相同。BayMedica本季度作爲盈利業務部門運營，並在降低製造成本方面繼續取得進展，隨着時間的推移，這將逐步提高利潤率。儘管我們對稀有大麻素行業的長期增長潛力持樂觀態度，但我們預計未來幾個季度的收入將波動。
Financial and Corporate Highlights:
財務和企業亮點：
- Net loss was $5.7 million for the quarter ended March 31, 2024, compared to a net loss of $7.6 million in the same period last year.
- 截至2024年3月31日的季度淨虧損爲570萬美元，而去年同期的淨虧損爲760萬美元。
- Research and development and patents expenses were $2.6 million for the nine months ended March 31, 2024, compared with $3.1 million for the nine months ended March 31, 2023.
- 截至2024年3月31日的九個月中，研發和專利費用爲260萬美元，而截至2023年3月31日的九個月爲310萬美元。
- General and administrative expenses were $4 million for the nine months ended March 31, 2024, compared with $4.4 million for the same period last year.
- 截至2024年3月31日的九個月中，一般和管理費用爲400萬美元，而去年同期爲440萬美元。
- As of March 31, 2023, the Company's cash, cash equivalents and short-term investments were $7.6 million, which compares to $8.9 million on June 30, 2023.
- 截至2023年3月31日，該公司的現金、現金等價物和短期投資爲760萬美元，而2023年6月30日爲890萬美元。
Based on current forecasts, the Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditure requirements into the fourth quarter of calendar year 2024, depending on the level and timing of realizing BayMedica revenues from the sale of products in the Health & Wellness sector as well as the level and timing of our operating expenses.
根據目前的預測，該公司預計，其現金將足以爲2024日曆年第四季度的計劃運營費用和資本支出需求提供資金，具體取決於BayMedica通過銷售健康與保健領域產品實現收入的水平和時間以及我們的運營支出水平和時間。
Ms. Alexandra D.J. Mancini, Senior Vice President, Clinical & Regulatory Affairs, provided notice to the Company and the Company's Board of Directors of her intention to retire from her position, effective June 30, 2024. Ms. Mancini intends to continue in a consultancy capacity to ensure a smooth transition of both the INM-755 program and ongoing regulatory matters. The Company would like to thank Ms. Mancini for her significant, valuable contributions, and leadership during her tenure with InMed and wish her all the best in her retirement. We congratulate her on a tremendous career in the biotech industry, having played an important role in developing and bringing to market several pharmaceutical products in many disease areas.
臨床與監管事務高級副總裁亞歷山德拉·曼奇尼女士通知公司和公司董事會，她打算從2024年6月30日起退休。曼奇尼女士打算繼續擔任諮詢職務，以確保 INM-755 計劃和正在進行的監管事務的平穩過渡。公司要感謝曼奇尼女士在InMed任職期間所做的重大而寶貴的貢獻和領導能力，並祝願她在退休後一切順利。我們祝賀她在生物技術行業取得了輝煌的職業生涯，在許多疾病領域的多種藥品開發和推向市場方面發揮了重要作用。
Table 1. InMed Pharmaceuticals Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
Expressed in U.S. Dollars
表 1。InMed 製藥公司
簡明的合併資產負債表
以美元表示
| March 31, | ||||||||
| 2024 | June 30, | |||||||
| (unaudited) | 2023 | |||||||
| $ | $ | |||||||
| ASSETS | ||||||||
| Current | ||||||||
| Cash and cash equivalents | 7,600,598 | 8,912,517 | ||||||
| Short-term investments | 43,085 | 44,422 | ||||||
| Accounts receivable, net of allowance for credit losses of $66,775 in 2024 and 2023 | 207,681 | 260,399 | ||||||
| Inventories | 1,193,952 | 1,616,356 | ||||||
| Prepaids and other current assets | 1,018,686 | 498,033 | ||||||
| Total current assets | 10,064,002 | 11,331,727 | ||||||
| Non-Current | ||||||||
| Property, equipment and ROU assets, net | 1,370,969 | 723,426 | ||||||
| Intangible assets, net | 1,823,745 | 1,946,279 | ||||||
| Other assets | 100,000 | 104,908 | ||||||
| Total Assets | 13,358,716 | 14,106,340 | ||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| Current | ||||||||
| Accounts payable and accrued liabilities | 1,183,285 | 1,608,735 | ||||||
| Current portion of lease obligations | 345,545 | 375,713 | ||||||
| Deferred rent | – | 16,171 | ||||||
| Total current liabilities | 1,528,830 | 2,000,619 | ||||||
| Non-current | ||||||||
| Lease obligations, net of current portion | 725,236 | 15,994 | ||||||
| Total Liabilities | 2,254,066 | 2,016,613 | ||||||
| Commitments and Contingencies | ||||||||
| Shareholders' Equity | ||||||||
| Common shares, no par value, unlimited authorized shares: | ||||||||
| 6,344,970 (June 30, 2023 – 3,328,191) issued and outstanding | 80,606,863 | 77,620,252 | ||||||
| Additional paid-in capital | 37,507,306 | 35,741,115 | ||||||
| Accumulated deficit | (107,138,088) | (101,400,209) | ||||||
| Accumulated other comprehensive income | 128,569 | 128,569 | ||||||
| Total Shareholders' Equity | 11,104,650 | 12,089,727 | ||||||
| Total Liabilities and Shareholders' Equity | 13,358,716 | 14,106,340 | ||||||
| Related Party Transactions | ||||||||
| Subsequent Events | ||||||||
| 3月31日 | ||||||||
| 2024 | 6月30日 | |||||||
| （未經審計） | 2023 | |||||||
| $ | $ | |||||||
| 資產 | ||||||||
| 當前 | ||||||||
| 現金和現金等價物 | 7,600,598 | 8,912,517 | ||||||
| 短期投資 | 43,085 | 44,422 | ||||||
| 應收賬款，扣除2024年和2023年66,775美元的信貸損失備抵後 | 207,681 | 260,399 | ||||||
| 庫存 | 1,193,952 | 1,616,356 | ||||||
| 預付費和其他流動資產 | 1,018,686 | 498,033 | ||||||
| 流動資產總額 | 10,064,002 | 11,331,727 | ||||||
| 非當前 | ||||||||
| 不動產、設備和ROU資產，淨額 | 1,370,969 | 723,426 | ||||||
| 無形資產，淨額 | 1,823,745 | 1,946,279 | ||||||
| 其他資產 | 10萬 | 104,908 | ||||||
| 總資產 | 13,358,716 | 14,106,340 | ||||||
| 負債和股東權益 | ||||||||
| 當前 | ||||||||
| 應付賬款和應計負債 | 1,183,285 | 1,608,735 | ||||||
| 租賃債務的當前部分 | 345,545 | 375,713 | ||||||
| 遞延租金 | — | 16,171 | ||||||
| 流動負債總額 | 1,528,830 | 2,000,619 | ||||||
| 非當前 | ||||||||
| 租賃債務，減去流動部分 | 725,236 | 15,994 | ||||||
| 負債總額 | 2,254,066 | 2,016,613 | ||||||
| 承付款和或有開支 | ||||||||
| 股東權益 | ||||||||
| 普通股，無面值，無限授權股： | ||||||||
| 6,344,970（2023 年 6 月 30 日 — 3,328,191）已發行和未償還 | 80,606,863 | 77,620,252 | ||||||
| 額外的實收資本 | 37,507,306 | 35,741,115 | ||||||
| 累計赤字 | (107,138,088) | (101,400,209) | ||||||
| 累計其他綜合收益 | 128,569 | 128,569 | ||||||
| 股東權益總額 | 11,104,650 | 12,089,727 | ||||||
| 負債和股東權益總額 | 13,358,716 | 14,106,340 | ||||||
| 關聯方交易 | ||||||||
| 後續事件 | ||||||||
Table 2. InMed Pharmaceuticals Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
Expressed in U.S. Dollars
表 2.InMed 製藥公司
簡明合併運營報表（未經審計）
以美元表示
| For the Three Months Ended | For the Nine Months Ended | |||||||||||
| 31-Mar | 31-Mar | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| $ | $ | $ | $ | |||||||||
| Sales | 1,172,601 | 1,033,925 | 3,314,663 | 1,824,496 | ||||||||
| Cost of sales | 883,143 | 841,414 | 2,416,417 | 1,415,068 | ||||||||
| Inventory write-down | – | – | 263,404 | 576,772 | ||||||||
| Gross profit | 289,458 | 192,511 | 634,842 | (167,344) | ||||||||
| Operating Expenses | ||||||||||||
| Research and development and patents | 656,764 | 878,303 | 2,558,648 | 3,108,312 | ||||||||
| General and administrative | 1,374,095 | 1,412,727 | 4,036,784 | 4,438,083 | ||||||||
| Amortization and depreciation | 54,767 | 50,689 | 164,833 | 148,786 | ||||||||
| Foreign exchange loss | 48,156 | 2,733 | 36,717 | 79,287 | ||||||||
| Total operating expenses | 2,133,782 | 2,344,452 | 6,796,982 | 7,774,468 | ||||||||
| Other Income (Expense) | ||||||||||||
| Interest and other income | 121,458 | 155,497 | 424,261 | 343,881 | ||||||||
| Loss before income taxes | (1,722,866) | (1,996,444) | (5,737,879) | (7,597,931) | ||||||||
| Tax expense | – | (1,500) | – | (11,300) | ||||||||
| Net loss for the period | (1,722,866) | (1,997,944) | (5,737,879) | (7,609,231) | ||||||||
| Net loss per share for the period | ||||||||||||
| Basic and diluted | (0.18) | (0.60) | (0.82) | (3.53) | ||||||||
| Weighted average outstanding common shares | ||||||||||||
| Basic and diluted | 9,612,973 | 3,328,191 | 6,961,938 | 2,156,283 | ||||||||
| 在已結束的三個月中 | 在結束的九個月裏 | |||||||||||
| 3 月 31 日 | 3 月 31 日 | |||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||
| $ | $ | $ | $ | |||||||||
| 銷售 | 1,172,601 | 1,033,925 | 3,314,663 | 1,824,496 | ||||||||
| 銷售成本 | 883,143 | 841,414 | 2,416,417 | 1,415,068 | ||||||||
| 庫存減記 | — | — | 263,404 | 576,772 | ||||||||
| 毛利 | 289,458 | 192,511 | 634,842 | (167,344) | ||||||||
| 運營費用 | ||||||||||||
| 研究與開發和專利 | 656,764 | 878,303 | 2,558,648 | 3,108,312 | ||||||||
| 一般和行政 | 1,374,095 | 1,412,727 | 4,036,784 | 4,438,083 | ||||||||
| 攤銷和折舊 | 54,767 | 50,689 | 164,833 | 148,786 | ||||||||
| 外匯損失 | 48,156 | 2,733 | 36,717 | 79,287 | ||||||||
| 運營費用總額 | 2,133,782 | 2,344,452 | 6,796,982 | 7,774,468 | ||||||||
| 其他收入（支出） | ||||||||||||
| 利息和其他收入 | 121,458 | 155,497 | 424,261 | 343,881 | ||||||||
| 所得稅前虧損 | (1,722,866) | (1,996,444) | (5,737,879) | (7,597,931) | ||||||||
| 稅收支出 | — | (1,500) | — | (11,300) | ||||||||
| 該期間的淨虧損 | (1,722,866) | (1,997,944) | (5,737,879) | (7,609,231) | ||||||||
| 該期間的每股淨虧損 | ||||||||||||
| 基本款和稀釋版 | (0.18) | (0.60) | (0.82) | (3.53) | ||||||||
| 加權平均已發行普通股 | ||||||||||||
| 基本款和稀釋版 | 9,612,973 | 3,328,191 | 6,961,938 | 2,156,283 | ||||||||
Table 3. InMed Pharmaceuticals Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
Expressed in U.S. Dollars
表 3.InMed 製藥公司
簡明合併現金流量表（未經審計）
以美元表示
| March 31, | March 31, | ||||||
| 2024 | 2023 | ||||||
| $ | $ | ||||||
| Cash provided by (used in): | |||||||
| Operating Activities | |||||||
| Net loss | (5,737,879) | (7,609,231) | |||||
| Items not requiring cash: | |||||||
| Amortization and depreciation | 164,833 | 148,786 | |||||
| Share-based compensation | 98,760 | 237,675 | |||||
| Amortization of right-of-use assets | 287,824 | 296,239 | |||||
| Interest income on short-term investments | (1,271) | (392) | |||||
| Unrealized foreign exchange loss | 2,607 | 2,138 | |||||
| Inventory write-down | 263,404 | 576,772 | |||||
| Bad debts | – | 25,085 | |||||
| Changes in operating assets and liabilities: | |||||||
| Inventories | 159,000 | 584,151 | |||||
| Prepaids and other current assets | (520,653) | 102,022 | |||||
| Other non-current assets | 4,908 | 5,507 | |||||
| Accounts receivable | 52,718 | (107,357) | |||||
| Accounts payable and accrued liabilities | (425,446) | (585,341) | |||||
| Deferred rent | (16,171) | 16,171 | |||||
| Lease obligations | (289,302) | (317,490) | |||||
| Total cash used in operating activities | (5,956,668) | (6,625,265) | |||||
| Investing Activities | |||||||
| Payment of acquisition consideration | – | (500,000) | |||||
| Sale of short-term investments | 42,513 | – | |||||
| Purchase of short-term investments | (42,513) | – | |||||
| Purchase of property and equipment | (9,293) | (128198) | |||||
| Total cash used in investing activities | (9,293) | (628,198) | |||||
| Financing Activities | |||||||
| Proceeds from private placement | 4,654,042 | 10,680,654 | |||||
| Total cash provided by financing activities | 4,654,042 | 10,680,654 | |||||
| (Decrease) increase in cash and cash equivalents during the period | (1,311,919) | 3,427,191 | |||||
| Cash and cash equivalents beginning of the period | 8,912,517 | 6,176,866 | |||||
| Cash and cash equivalents end of the period | 7,600,598 | 9,604,057 | |||||
| SUPPLEMENTARY CASH FLOW INFORMATION: | |||||||
| Cash Paid During the Year for: | |||||||
| Income taxes | $ | – | $ | 11,300 | |||
| Interest | $ | – | $ | – | |||
| SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | |||||||
| Fair value of warrant modification recorded as equity issuance costs | $ | 3,508,749 | $ | – | |||
| Preferred investment options to its placement agent | $ | 325,699 | $ | 691,483 | |||
| Recognition of Right-of-use asset and corresponding operating lease liability | $ | 968,376 | $ | – | |||
| 3月31日 | 3月31日 | ||||||
| 2024 | 2023 | ||||||
| $ | $ | ||||||
| 提供的現金（用於）： | |||||||
| 運營活動 | |||||||
| 淨虧損 | (5,737,879) | (7,609,231) | |||||
| 不需要現金的物品： | |||||||
| 攤銷和折舊 | 164,833 | 148,786 | |||||
| 基於股份的薪酬 | 98,760 | 237,675 | |||||
| 使用權資產的攤銷 | 287,824 | 296,239 | |||||
| 短期投資的利息收入 | (1,271) | (392) | |||||
| 未實現的外匯損失 | 2,607 | 2,138 | |||||
| 庫存減記 | 263,404 | 576,772 | |||||
| 壞賬 | — | 25,085 | |||||
| 運營資產和負債的變化： | |||||||
| 庫存 | 159,000 | 584,151 | |||||
| 預付費和其他流動資產 | (520,653) | 102,022 | |||||
| 其他非流動資產 | 4,908 | 5,507 | |||||
| 應收賬款 | 52,718 | (107,357) | |||||
| 應付賬款和應計負債 | (425,446) | (585,341) | |||||
| 遞延租金 | (16,171) | 16,171 | |||||
| 租賃義務 | (289,302) | (317,490) | |||||
| 用於經營活動的現金總額 | (5,956,668) | (6,625,265) | |||||
| 投資活動 | |||||||
| 收購對價的支付 | — | (500,000) | |||||
| 出售短期投資 | 42,513 | — | |||||
| 購買短期投資 | (42,513) | — | |||||
| 購買財產和設備 | (9,293) | (128198) | |||||
| 用於投資活動的現金總額 | (9,293) | (628,198) | |||||
| 融資活動 | |||||||
| 私募收益 | 4,654,042 | 10,680,654 | |||||
| 融資活動提供的現金總額 | 4,654,042 | 10,680,654 | |||||
| 該期間現金及現金等價物 (減少) 增加 | (1,311,919) | 3,427,191 | |||||
| 期初的現金和現金等價物 | 8,912,517 | 6,176,866 | |||||
| 期末現金和現金等價物 | 7,600,598 | 9,604,057 | |||||
| 補充現金流信息： | |||||||
| 年內爲以下各項支付的現金： | |||||||
| 所得稅 | $ | — | $ | 11,300 | |||
| 利息 | $ | — | $ | — | |||
| 非現金投資和融資活動的補充披露： | |||||||
| 認股權證修改的公允價值記作股票發行成本 | $ | 3,508,749 | $ | — | |||
| 其配售代理的首選投資選擇 | $ | 325,699 | $ | 691,483 | |||
| 確認使用權資產和相應的經營租賃負債 | $ | 968,376 | $ | — | |||
About InMed:
關於 inMed：
InMed Pharmaceuticals is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with its subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. For more information, visit www.inmedpharma.com.
InMed Pharmaceuticals是一家臨床階段的製藥公司，專注於開發針對CB1/CB2受體的專有小分子候選藥物管道。InMed的產品線包括三個單獨的項目，分別治療阿爾茨海默氏症、眼部和皮膚病學適應症。我們及其子公司BayMedica是稀有大麻素和專有大麻素類似物的製造、開發和商業化的全球領導者。欲了解更多信息，請訪問 www.inmedpharma.com。
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E: [email protected]
投資者聯繫人：
科林·克蘭西
投資者關係副總裁
和企業傳播
電話：+1 604 416 0999
E: [電子郵件保護]
Cautionary Note Regarding Forward-Looking Information:
關於前瞻性信息的警示說明：
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901, the results of further studies into INM-901 and acceleration of the development of InMed's Alzheimer's program; the efficacy of INM-089, INM-089's ability to treat AMD, marketability and uses for INM-089, the results of further studies into INM-089 and the further development of InMed's AMD program; being optimistic about the long-term growth potential in the rare cannabinoids sector; improving margins over time; expectations that the Company's cash will be sufficient to fund its planned operating expenses and capital expenditure requirements into the fourth quarter of calendar year 2024.
本新聞稿包含適用證券法所指的 “前瞻性信息” 和 “前瞻性陳述”（統稱爲 “前瞻性信息”）。前瞻性陳述通常以 “期望”、“預期”、“相信”、“打算”、“潛力”、“可能”、“將” 等詞語和類似表述來識別，但並非總是如此。此類陳述基於管理層當前的預期，本質上涉及許多已知和未知的風險、不確定性和假設，其中許多是我們無法控制的。前瞻性信息基於管理層當前的預期和信念，存在許多風險和不確定性，這些風險和不確定性可能導致實際業績與前瞻性陳述中描述的結果存在重大差異。在不限制上述內容的情況下，本新聞稿中的前瞻性信息包括但不限於以下方面的陳述：INM-901 的功效、INM-901 治療阿爾茨海默氏症的能力、INM-901 的適銷性和用途、對 INM-901 的進一步研究結果以及 InMed 阿爾茨海默氏症計劃的加速發展；INM-089 的功效、INM-089 的治療 AMD 的能力、INM-089 的適銷性和用途、inINM-089 的進一步研究和進一步發展的結果 Med 的 AMD 計劃；對長期持樂觀態度稀有大麻素行業的增長潛力；隨着時間的推移利潤率的提高；預計公司的現金將足以爲2024日曆年第四季度的計劃運營費用和資本支出需求提供資金。
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.
此外，還有一些已知和未知的風險因素可能導致InMed的實際業績、業績或成就與本文所包含的前瞻性信息所表達或暗示的任何未來業績、業績或成就存在重大差異。InMed的10-K表年度報告和向美國證券交易委員會提交的其他文件中披露了對InMed獨立業務面臨的風險和不確定性的全面討論 www.sec.gov。
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
此處的所有前瞻性信息均受本警示聲明的全面限制，除非法律要求，否則InMed不承擔任何修改或更新任何此類前瞻性信息或公開宣佈爲反映未來業績、事件或發展而對本文包含的任何前瞻性信息進行任何修訂的結果的義務。
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/209046
要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/209046
譯文內容由第三人軟體翻譯。